---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-245404"
form_type: "8-K"
ticker: "TERN"
cik: "0001831363"
company_name: "Terns Pharmaceuticals, Inc."
filed_at: "2025-10-22T23:59:59+00:00"
generated_at: "2026-05-17T02:48:21.366784+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Terns Pharma discontinues obesity drug TERN-601 after Phase 2 miss; liver enzyme signals seen

## Summary
- Max placebo-adjusted weight loss 4.6% (p<0.0001) at 500 mg dose; 11.9% discontinued due to AEs.
- Grade 3 liver enzyme elevations in 3 participants post-treatment, 2 deemed drug-related.
- Company will not advance TERN-601 or further invest in metabolic assets.
- Reiterates focus on TERN-701 for CML with clinical data expected this quarter.
- GI AEs most common: nausea 56%, vomiting 26.9%; all mild/moderate and dose-related.

## SEC filing metadata
- accession: 0001193125-25-245404
- form_type: 8-K
- ticker: TERN
- cik: 0001831363
- company_name: Terns Pharmaceuticals, Inc.
- filed_at: 2025-10-22T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831363/000119312525245404/0001193125-25-245404-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831363/000119312525245404/d14463d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-245404
- JSON: https://secwatch.observer/filing/0001193125-25-245404.json
- Plain text: https://secwatch.observer/filing/0001193125-25-245404.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.